A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Public ClinicalTrials.gov record NCT05410145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Study identification
- NCT ID
- NCT05410145
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- D3 Bio (Wuxi) Co., Ltd
- Industry
- Enrollment
- 442 participants
Conditions and interventions
Conditions
Interventions
- D3S-001 Drug
- Pembrolizumab Drug
- Cisplatin Drug
- Carboplatin Drug
- Pemetrexed Drug
- Cetuximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2, 2022
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
- Last update posted
- Mar 11, 2026
2022 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| D3 Bio Investigative Site 0402 | Orange | California | 92868 | Recruiting |
| D3 Bio Investigative Site 0407 | Palo Alto | California | 94304-2205 | Recruiting |
| D3 Bio Investigative Site 0404 | Denver | Colorado | 80218-1238 | Recruiting |
| D3 Bio Investigative Site 0406 | Sarasota | Florida | 34232-6410 | Recruiting |
| D3 Bio Investigative Site 0401 | Detroit | Michigan | 48202-2608 | Recruiting |
| D3 Bio Investigative Site 0405 | Nashville | Tennessee | 37203 | Recruiting |
| D3 Bio Investigative Site 0403 | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05410145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05410145 live on ClinicalTrials.gov.